Congress quietly targets drug discounts for undocumented immigrants in Medicaid
H.R. 1195 — Protect Medicaid Act · Filed by Richard Hudson (R-NC) · 16 cosponsors · Introduced Feb 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits federal Medicaid funding from paying for the administrative costs of state programs that provide health benefits to unauthorized immigrants. It requires the HHS Inspector General to report within 180 days on how states separate and finance such programs, including examination of whether unauthorized immigrants receive discounted drugs through federal rebate programs and whether this affects drug pricing.
Why we flagged it
The bill's stated purpose is administrative cost prohibition, but the Inspector General report requirements—particularly the detailed drug-pricing analysis—suggest a secondary intent to restrict pharmaceutical discounts for unauthorized immigrants and potentially reshape Medicaid drug-rebate mechanics.
What the text implies
- The drug-pricing analysis (Section 3, subparagraph analyzing 'average manufacturer price') may be designed to build a case for excluding unauthorized immigrants from the Medicaid Drug Rebate Program entirely, which could increase drug costs for all Medicaid beneficiaries if rebate pools shrink.
- Shifting administrative costs to states may incentivize states to reduce or eliminate health programs for unauthorized immigrants, potentially increasing uncompensated emergency-room care and public-health costs that fall on hospitals and local governments.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (if drug-rebate restrictions reduce discounts); private health insurers (reduced Medicaid competition); for-profit hospital chains (UHS, HCA, Tenet) if uncompensated care shifts to them